What sets Fabtech apart is its unique end-to-end turnkey approach, manufacturing core systems for Process, Air, and Water in-house. This strategy ensures unparalleled quality, speed, and cost control for its pharma, biotech, and healthcare clients across 62+ countries.
The FY26 results underscore a period of resilient growth and strategic advancement:
FY26 Performance Highlights:
- Revenue from Operations: ₹410.77 Crore, a robust 25.7% year-over-year increase.
- Operational Profit: ₹36.60 Crore, up 17.0% from the previous fiscal year.
- Order Book: A commanding ₹900+ Crore, providing significant revenue visibility for upcoming periods.
Despite global freight volatility and geopolitical disruptions, Fabtech demonstrated strong operational continuity. Strategic moves into UAE and Saudi localization, new joint ventures, and a key European acquisition are extending its reach into premium, high-margin markets. The company’s entry into the Animal Health segment and major project wins in KSA and Africa further diversify its growth platform.
With a strong order book and a robust enquiry pipeline, Fabtech Technologies is well-positioned for sustained growth, actively shaping the future of global pharmaceutical manufacturing infrastructure. Investors should take note of this dynamic player building the backbone of global health.